Literature DB >> 28277128

Expression of cyclooxygenase-1 and cyclooxygenase-2, syndecan-1 and connective tissue growth factor in benign and malignant breast tissue from premenopausal women.

M Fahlén1,2,3, H Zhang3, L Löfgren1, B Masironi3, E von Schoultz2, B von Schoultz4, L Sahlin3.   

Abstract

Stromal factors have been identified as important for tumorigenesis and metastases of breast cancer. From 49 premenopausal women, samples were collected from benign or malignant tumors and the seemingly normal tissue adjacent to the tumor. The factors studied, with real-time polymerase chain reaction (PCR) and immunohistochemistry, were cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2), syndecan-1 (S-1) and connective tissue growth factor (CTGF). COX-1 and S-1 mRNA levels were higher in the malignant tumors than in normal and benign tissues. The COX-2 mRNA level was lower in the malignant tumor than in the normal tissue, while CTGF mRNA did not differ between the groups. COX-1 immunostaining was higher in stroma from malignant tumors than in benign tissues, whereas COX-2 immunostaining was higher in the malignant tissue. Glandular S-1 immunostaining was lower in malignant tumors compared to benign and normal tissues, and the opposite was found in stroma. Conclusively, mRNA levels of COX-1 and COX-2 were oppositely regulated, with COX-1 being increased in the malignant tumor while COX-2 was decreased. S-1 protein localization switched from glandular to stromal cells in malignant tissues. Thus, these markers are, in premenopausal women, localized and regulated differently in normal/benign breast tissue as compared to the malignant tumor.

Entities:  

Keywords:  CTGF; Premenopausal; breast; cyclooxygenase; syndecan-1

Mesh:

Substances:

Year:  2017        PMID: 28277128     DOI: 10.1080/09513590.2016.1260109

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  2 in total

1.  S-nitrosylated and non-nitrosylated COX2 have differential expression and distinct subcellular localization in normal and breast cancer tissue.

Authors:  Sonali Jindal; Nathan D Pennock; Alex Klug; Jayasri Narasimhan; Andrea Calhoun; Michelle R Roberts; Rulla M Tamimi; A Heather Eliassen; Sheila Weinmann; Virginia F Borges; Pepper Schedin
Journal:  NPJ Breast Cancer       Date:  2020-11-24

2.  Cytoplasmic PPARγ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers.

Authors:  Wanting Shao; Christina Kuhn; Doris Mayr; Nina Ditsch; Magdalena Kailuwait; Verena Wolf; Nadia Harbeck; Sven Mahner; Udo Jeschke; Vincent Cavaillès; Sophie Sixou
Journal:  J Transl Med       Date:  2020-02-21       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.